Grape seed procyanidin B2 promotes the autophagy and apoptosis in colorectal cancer cells via regulating PI3K/Akt signaling pathway

Colorectal cancer (CRC) is a major malignancy in China, which is the critical risk of people health. Many natural herbs extracts have been found to exhibit good therapeutic effect on CRC. Our previous study found that grape seed procyanidins B2 (PB2) would induce CRC cell death. However, the molecul...

Full description

Saved in:
Bibliographic Details
Published in:OncoTargets and therapy 2019-05, Vol.12, p.4109-4118
Main Authors: Zhang, Ruijuan, Yu, Qianyun, Lu, Wenqiang, Shen, Jun, Zhou, Dongqing, Wang, Yingjue, Gao, Shurong, Wang, Zhijun
Format: Article
Language:English
Subjects:
Apoptosis
Biochemistry
Cancer cells
Cancer research
Cell death
Colorectal cancer
Health
Health aspects
Original Research
Seeds
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Colorectal cancer (CRC) is a major malignancy in China, which is the critical risk of people health. Many natural herbs extracts have been found to exhibit good therapeutic effect on CRC. Our previous study found that grape seed procyanidins B2 (PB2) would induce CRC cell death. However, the molecular mechanism underlying its anti-tumor effect on CRC remains unclear. Thereby, this study aimed to investigate the anti-tumor mechanism of PB2 on CRC. CCK-8, western blotting, flow cytometry, qRT-PCR and animal study were used in the current study. The in vitro and in vivo data demonstrated that PB2 could promote the apoptosis of CRC cells in a dose-dependent manner, which was significantly reversed by caspase 3 inhibitor. Meanwhile, PB2 dose-dependently induced autophagy in CRC cells, which was markedly attenuated by autophagy inhibitor 3-MA. In addition, PB2 dose-dependently inhibited the expressions of p-PI3K, p-Akt and p-mTOR in the cells. PB2 dose-dependently induced apoptosis and autophagy in CRC cells via downregulation of PI3K/Akt pathway. This study provided the experimental basis for further development of PB2 as a new effective anticancer drug for the patients with CRC.
ISSN:1178-6930
1178-6930
DOI:10.2147/OTT.S195615